A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Overview

This is a first in Chinese population study to evaluate the safety, tolerability, PK and PD of multiple dose of modified-release IBI353 administered orally in healthy subjects. The study enrolls 20 healthy subjects and consists of 1 week of screening, 3 weeks of treatment period and 1 week of safety follow up after completion of last dose.

Full Title of Study: “A Phase I Randomized, Double-Blind, Placebo-Controlled, Multiple Oral Dose Trial to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IBI353 (Orismilast) in Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 31, 2023

Interventions

  • Drug: IBI353 (Orismilast)
    • dose 1 or dose 2
  • Drug: placebo
    • placebo

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo tablet
  • Experimental: IBI353 (Orismilast) dose 2
  • Experimental: IBI353 (Orismilast) dose 1

Clinical Trial Outcome Measures

Primary Measures

  • Time to Maximal Blood Concentration (Tmax) of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21
  • Maximal Concentration (Cmax) of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21
  • Area Under the Concentration Curve (AUC) of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21
  • Volume of Distribution (Vd/F) of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21
  • Half life time of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21
  • Clearance (CL/F) of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21
  • Accumulation Ratio of IBI353 and its related metabolites.
    • Time Frame: Baseline through Day 21

Secondary Measures

  • Incidence of treatment-emergent adverse events (TEAEs), gastrointestinal AEs, and changes of vital signs, lab examinations, physical examinations, ECGs in healthy subjects after drug administration.
    • Time Frame: Baseline through Day 28

Participating in This Clinical Trial

Inclusion Criteria

1. Healthy male or female 18 to 45 years of age at the time of consent 2. BMI of 19-27Kg/m2 and weight of 50-100kg (male) or 45-100kg (female) 3. Participants are in good health condition at screening stage based on past history, lab tests, EEG, physical examinations, and vital signs. 4. Must provide written informed consent, and in the investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements Exclusion Criteria:

1. Subjects who have a medical history of liver, kidney, cardiovascular, nervous / mental, gastrointestinal, respiratory, urinary, endocrine system; 2. Subjects who have a history of relapse or chronic infection, or a history of acute infection treated by antibiotics within 3 months; 3. Subjects who have previously used PDE4 inhibitor dugs; 4. Subjects who have clinically significant abnormalities determined by vital signs, physical examination, and laboratory measurements; 5. Subjects who are not suitable for this trial due to other reasons In the investigator' opinion

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Innovent Biologics (Suzhou) Co. Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Jing Zhang, 086-13816357098, 13816357098@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.